{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:33:45Z","timestamp":1767918825596,"version":"3.49.0"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"national research foundation","doi-asserted-by":"crossref","award":["NRF-2019R1A2C1090219"],"award-info":[{"award-number":["NRF-2019R1A2C1090219"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003693","name":"korea institute of science and technology","doi-asserted-by":"crossref","award":["2K02610"],"award-info":[{"award-number":["2K02610"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003693","name":"korea institute of science and technology","doi-asserted-by":"crossref","award":["2Z0663"],"award-info":[{"award-number":["2Z0663"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001321","name":"national research foundation","doi-asserted-by":"crossref","award":["2020R1F1A1073114"],"award-info":[{"award-number":["2020R1F1A1073114"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>A long-standing practice in the treatment of cancer is that of hitting hard with the maximum tolerated dose to eradicate tumors. This continuous therapy, however, selects for resistant cells, leading to the failure of the treatment. A different type of treatment strategy, adaptive therapy, has recently been shown to have a degree of success in both preclinical xenograft experiments and clinical trials. Adaptive therapy is used to maintain a tumor\u2019s volume by exploiting the competition between drug-sensitive and drug-resistant cells with minimum effective drug doses or timed drug holidays. To further understand the role of competition in the outcomes of adaptive therapy, we developed a 2D on-lattice agent-based model. Our simulations show that the superiority of the adaptive strategy over continuous therapy depends on the local competition shaped by the spatial distribution of resistant cells. Intratumor competition can also be affected by fibroblasts, which produce microenvironmental factors that promote cancer cell growth. To this end, we simulated the impact of different fibroblast distributions on treatment outcomes. As a proof of principle, we focused on five types of distribution of fibroblasts characterized by different locations, shapes, and orientations of the fibroblast region with respect to the resistant cells. Our simulation shows that the spatial architecture of fibroblasts modulates tumor progression in both continuous and adaptive therapy. Finally, as a proof of concept, we simulated the outcomes of adaptive therapy of a virtual patient with four metastatic sites composed of different spatial distributions of fibroblasts and drug-resistant cell populations. Our simulation highlights the importance of undetected metastatic lesions on adaptive therapy outcomes.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1009919","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T18:31:07Z","timestamp":1646850667000},"page":"e1009919","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-7424","authenticated-orcid":true,"given":"Masud","family":"M A","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-1372","authenticated-orcid":true,"given":"Jae-Young","family":"Kim","sequence":"additional","affiliation":[]},{"given":"Cheol-Ho","family":"Pan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-2805","authenticated-orcid":true,"given":"Eunjung","family":"Kim","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"issue":"2","key":"pcbi.1009919.ref001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"D Longley","year":"2005","journal-title":"The Journal of Pathology"},{"key":"pcbi.1009919.ref002","first-page":"1","volume-title":"Overview of Resistance to Systemic Therapy in Patients with Breast Cancer","author":"AM Gonzalez-Angulo","year":"2007"},{"issue":"9","key":"pcbi.1009919.ref003","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"PA Ascierto","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"10","key":"pcbi.1009919.ref004","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"R Dummer","year":"2018","journal-title":"The Lancet Oncology"},{"issue":"13","key":"pcbi.1009919.ref005","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1158\/1078-0432.CCR-14-1213","article-title":"Intratumoral Heterogeneity: From Diversity Comes Resistance","volume":"21","author":"A Pribluda","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"pcbi.1009919.ref006","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance","volume":"37","author":"A Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"pcbi.1009919.ref007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fonc.2013.00111","article-title":"The Role of Tumor Tissue Architecture in Treatment Penetration and Efficacy: An Integrative Study","volume":"3","author":"K Rejniak","year":"2013","journal-title":"Frontiers in Oncology"},{"issue":"7782","key":"pcbi.1009919.ref008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"N Vasan","year":"2019","journal-title":"Nature"},{"issue":"12","key":"pcbi.1009919.ref009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123716","article-title":"Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness","volume":"12","author":"R Hass","year":"2020","journal-title":"Cancers"},{"key":"pcbi.1009919.ref010","doi-asserted-by":"crossref","DOI":"10.4137\/CIN.S19338","article-title":"The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells","volume":"14s4","author":"SM Mumenthaler","year":"2015","journal-title":"Cancer Informatics"},{"key":"pcbi.1009919.ref011","first-page":"135","volume-title":"Lotka\u2013Volterra Interspecific Competition","author":"MHH Stevens","year":"2009"},{"key":"pcbi.1009919.ref012","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/459508a","article-title":"A change of strategy in the war on cancer","volume":"459","author":"R Gatenby","year":"2009","journal-title":"Nature"},{"key":"pcbi.1009919.ref013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3897\/rethinkingecology.3.31992","article-title":"Cost of resistance: an unreasonably expensive concept","volume":"3","author":"T Lenormand","year":"2018","journal-title":"Rethinking Ecology"},{"issue":"11","key":"pcbi.1009919.ref014","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive Therapy","volume":"69","author":"RA Gatenby","year":"2009","journal-title":"Cancer Research"},{"issue":"11","key":"pcbi.1009919.ref015","article-title":"The Evolution and Ecology of Resistance in Cancer Therapy","volume":"10","author":"R Gatenby","year":"2020","journal-title":"Cold Spring Harbor perspectives in medicine"},{"key":"pcbi.1009919.ref016","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"J Zhang","year":"2017","journal-title":"Nature Communications"},{"issue":"24","key":"pcbi.1009919.ref017","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/0008-5472.CAN-12-2235","article-title":"Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer","volume":"72","author":"AS Silva","year":"2012","journal-title":"Cancer Research"},{"issue":"327","key":"pcbi.1009919.ref018","first-page":"327ra24","article-title":"Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer","volume":"8","author":"PM Enriquez-Navas","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"8","key":"pcbi.1009919.ref019","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","article-title":"Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies","volume":"78","author":"JA Gallaher","year":"2018","journal-title":"Cancer Research"},{"issue":"12","key":"pcbi.1009919.ref020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123556","article-title":"Modifying Adaptive Therapy to Enhance Competitive Suppression","volume":"12","author":"E Hansen","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"pcbi.1009919.ref021","article-title":"Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models","volume":"13","author":"E Kim","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"pcbi.1009919.ref022","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1158\/0008-5472.CAN-20-0806","article-title":"Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy","volume":"81","author":"MAR Strobl","year":"2021","journal-title":"Cancer Research"},{"issue":"14","key":"pcbi.1009919.ref023","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1158\/1078-0432.CCR-19-0006","article-title":"Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy","volume":"25","author":"JB West","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"pcbi.1009919.ref024","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","article-title":"Towards Multidrug Adaptive Therapy","volume":"80","author":"J West","year":"2020","journal-title":"Cancer Research"},{"key":"pcbi.1009919.ref025","article-title":"A theoretical analysis of tumour containment","author":"Y Viossat","year":"2021","journal-title":"Nature Ecology and Evolution"},{"issue":"1995","key":"pcbi.1009919.ref026","article-title":"Spatial competition constrains resistance to targeted cancer therapy","volume":"8","author":"K Bacevic","year":"2017","journal-title":"Nature communications"},{"key":"pcbi.1009919.ref027","article-title":"Spatial structure impacts adaptive therapy by shaping intra-tumoral competition","author":"MAR Strobl","year":"2021","journal-title":"bioRxiv"},{"issue":"9","key":"pcbi.1009919.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0006888","article-title":"Systems-Level Modeling of Cancer-Fibroblast Interaction","volume":"4","author":"RC Wadlow","year":"2009","journal-title":"PLOS ONE"},{"issue":"8","key":"pcbi.1009919.ref029","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bcp.2013.01.018","article-title":"Fibroblast-mediated drug resistance in cancer","volume":"85","author":"HTP Kim","year":"2013","journal-title":"Biochemical Pharmacology"},{"issue":"22","key":"pcbi.1009919.ref030","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1158\/0008-5472.CAN-16-1457","article-title":"Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes","volume":"76","author":"A Marusyk","year":"2016","journal-title":"Cancer Research"},{"issue":"3","key":"pcbi.1009919.ref031","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"E Sahai","year":"2020","journal-title":"Nature reviews Cancer"},{"issue":"6","key":"pcbi.1009919.ref032","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41559-020-1157-y","article-title":"Stromal Reactivity Differentially Drives Tumor Cell Evolution and Prostate Cancer Progression","volume":"4","author":"Z Frankenstein","year":"2020","journal-title":"Nature Ecology & Evolution"},{"issue":"11","key":"pcbi.1009919.ref033","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41388-021-01685-w","article-title":"Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis","volume":"40","author":"H Yoon","year":"2021","journal-title":"Oncogene"},{"issue":"15","key":"pcbi.1009919.ref034","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153743","article-title":"Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma","volume":"13","author":"NH Chakiryan","year":"2021","journal-title":"Cancers"},{"key":"pcbi.1009919.ref035","article-title":"Quantitative histology analysis of the ovarian tumour microenvironment","volume":"5","author":"C Lan","year":"2015","journal-title":"Scientific Reports"},{"key":"pcbi.1009919.ref036","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ebiom.2019.10.001","article-title":"Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer","volume":"48","author":"S Nawaz","year":"2019","journal-title":"EBioMedicine"},{"issue":"10","key":"pcbi.1009919.ref037","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/0008-5472.CAN-19-1629","article-title":"Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer","volume":"80","author":"S Wang","year":"2020","journal-title":"Cancer Research"},{"key":"pcbi.1009919.ref038","volume-title":"Ecology: concepts and applications","author":"MC Molles","year":"2008"},{"issue":"22","key":"pcbi.1009919.ref039","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"BT Gr\u00fcnwald","year":"2021","journal-title":"Cell"},{"issue":"14","key":"pcbi.1009919.ref040","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1158\/0008-5472.CAN-18-3652","article-title":"Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies","volume":"79","author":"C Grassberger","year":"2019","journal-title":"Cancer Research"},{"issue":"3","key":"pcbi.1009919.ref041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1007635","article-title":"Hybrid Automata Library: A flexible platform for hybrid modeling with real-time visualization","volume":"16","author":"RR Bravo","year":"2020","journal-title":"PLOS Computational Biology"},{"issue":"5","key":"pcbi.1009919.ref042","doi-asserted-by":"crossref","first-page":"056001","DOI":"10.1088\/1478-3975\/12\/5\/056001","article-title":"The evolution of carrying capacity in constrained and expanding tumour cell populations","volume":"12","author":"P Gerlee","year":"2015","journal-title":"Physical Biology"},{"issue":"1","key":"pcbi.1009919.ref043","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mehy.2006.11.007","article-title":"Cancer dissemination: A consequence of limited carrying capacity?","volume":"69","author":"TS Deisboeck","year":"2007","journal-title":"Medical Hypotheses"},{"issue":"5","key":"pcbi.1009919.ref044","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/19336918.2015.1061173","article-title":"Cancer cell migration in 3D tissue: Negotiating space by proteolysis and nuclear deformability","volume":"9","author":"M Krause","year":"2015","journal-title":"Cell Adhesion & Migration"},{"key":"pcbi.1009919.ref045","first-page":"67","volume-title":"Protocols for Migration and Invasion Studies in Prostate Cancer","author":"AF van de Merbel","year":"2018"},{"key":"pcbi.1009919.ref046","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcell.2019.00107","article-title":"In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis","volume":"7","author":"J Pijuan","year":"2019","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"pcbi.1009919.ref047","article-title":"The impact of tumor stromal architecture on therapy response and clinical progression","author":"PM Altrock","year":"2018","journal-title":"bioRxiv"},{"key":"pcbi.1009919.ref048","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22123-1","article-title":"Normal tissue architecture determines the evolutionary course of cancer","volume":"12","author":"J West","year":"2021","journal-title":"Nature Communications"},{"key":"pcbi.1009919.ref049","doi-asserted-by":"crossref","first-page":"17937","DOI":"10.1038\/s41598-018-36184-8","article-title":"High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts","volume":"8","author":"H Kim","year":"2018","journal-title":"Scientific Reports"},{"issue":"35","key":"pcbi.1009919.ref050","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1073\/pnas.1508074112","article-title":"Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination","volume":"112","author":"JZ Sanborn","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"pcbi.1009919.ref051","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"N McGranahan","year":"2017","journal-title":"Cell"},{"issue":"4","key":"pcbi.1009919.ref052","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrc.2017.126","article-title":"Genetic insights into the morass of metastatic heterogeneity","volume":"18","author":"KW Hunter","year":"2018","journal-title":"Nature reviews Cancer"},{"issue":"9","key":"pcbi.1009919.ref053","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1158\/0008-5472.CAN-20-3665","article-title":"Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer","volume":"81","author":"J Zhou","year":"2021","journal-title":"Cancer Research"},{"key":"pcbi.1009919.ref054","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"D Weinstein","year":"2014","journal-title":"The Journal of clinical and aesthetic dermatology"},{"key":"pcbi.1009919.ref055","first-page":"58","article-title":"Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer","volume":"6","author":"SF Shariat","year":"2004","journal-title":"Reviews in Urology"},{"key":"pcbi.1009919.ref056","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.stem.2012.03.009","article-title":"The PSA Prostate Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells that Resist Castration","volume":"10","author":"J Qin","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"5","key":"pcbi.1009919.ref057","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/2159-8290.CD-20-1187","article-title":"Thinking Differently about Cancer Treatment Regimens","volume":"11","author":"J Settleman","year":"2021","journal-title":"Cancer Discovery"},{"key":"pcbi.1009919.ref058","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1101\/gad.279737.116","article-title":"Carcinoma-associated fibroblasts: orchestrating the composition of malignancy","volume":"30","author":"P Gascard","year":"2016","journal-title":"Genes & Development"},{"key":"pcbi.1009919.ref059","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.3892\/ol.2017.6497","article-title":"Cancer associated fibroblasts: An essential role in the tumor microenvironment (Review)","volume":"14","author":"L Tao","year":"2017","journal-title":"Oncology Letters"},{"issue":"8","key":"pcbi.1009919.ref060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0042150","article-title":"Quantitative Model of Cell Cycle Arrest and Cellular Senescence in Primary Human Fibroblasts","volume":"7","author":"S Schauble","year":"2012","journal-title":"PLOS ONE"},{"issue":"5","key":"pcbi.1009919.ref061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0232965","article-title":"The double-edged sword role of fibroblasts in the interaction with cancer cells; an agent-based modeling approach","volume":"15","author":"Z Heidary","year":"2020","journal-title":"PLOS ONE"},{"issue":"3","key":"pcbi.1009919.ref062","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00285-009-0307-2","article-title":"Transformed epithelial cells and fibroblasts\/myofibroblasts interaction in breast tumor: a mathematical model and experiments","volume":"61","author":"Y Kim","year":"2010","journal-title":"Journal of mathematical biology"},{"issue":"3","key":"pcbi.1009919.ref063","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00441-014-2075-6","article-title":"Co-migration of colon cancer cells and CAFs induced by TGF enhances liver metastasis","volume":"359","author":"I Gonzalez-Zubeldia","year":"2015","journal-title":"Cell and tissue research"},{"key":"pcbi.1009919.ref064","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-019-0140-4","article-title":"LXR limits TGF-dependent hepatocellular carcinoma associated fibroblast differentiation","volume":"8","author":"A Moren","year":"2019","journal-title":"Oncogenesis"},{"issue":"11","key":"pcbi.1009919.ref065","doi-asserted-by":"crossref","first-page":"12357","DOI":"10.1021\/acsnano.9b04857","article-title":"Reshaping Prostate Tumor Microenvironment To Suppress Metastasis via Cancer-Associated Fibroblast Inactivation with Peptide-Assembly-Based Nanosystem","volume":"13","author":"J Lang","year":"2019","journal-title":"ACS Nano"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T18:32:20Z","timestamp":1646850740000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009919"}},"subtitle":[],"editor":[{"given":"Philip K","family":"Maini","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1009919","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]}}}